MedTrace Logo

Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy

NCT00503568 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2016-12-15

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells.

PURPOSE: This phase I trial is studying the effects of gp96-Ig vaccine therapy in treating patients with stage III, stage IV, or relapsed non-small cell lung cancer treated with first-line chemotherapy.

Conditions

Interventions

BIOLOGICAL

Ad100-gp96Ig-HLA A1

Dose Schedule 1 (DS-1): 4x10\^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10\^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10\^7 cells twice weekly, maximum 36 vaccines/patient

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Luis E. Raez, MD, FACP · University of Miami Sylvester Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00503568 on ClinicalTrials.gov